Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity
about
Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaquesProgesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs).Potential role of hCG in apoptosis of human luteinized granulosa cellsProgesterone antagonists and progesterone receptor modulators.The Effects of Sugammadex on Progesterone Levels in Pregnant RatsEmerging drugs in endometriosis.Utero-placental expression of angiotensin-(1-7) and ACE2 in the pregnant guinea-pig.Molecular mechanism of regulation of the calcium-binding protein calbindin-D9k, and its physiological role(s) in mammals: a review of current research.Vasodilator factors in the systemic and local adaptations to pregnancy.Effects of antiprogestins on the uterus.New and emerging contraceptives: a state-of-the-art review.Induction of the expressions of antioxidant enzymes by luteinizing hormone in the bovine corpus luteum.Emerging female contraceptives.Ulipristal acetate: a new emergency contraceptive.In vitro-assessment of putative antiprogestin activities of phytochemicals and synthetic UV absorbers in human endometrial Ishikawa cells.Inhibition of proliferation of endometrial stromal cells by trichostatin A, RU486, CDB-2914, N-acetylcysteine, and ICI 182780.Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies.Gynaecological uses of a new class of steroids: the selective progesterone receptor modulators.Stabilization of protein-protein interactions in drug discovery.Effects of ulipristal acetate on sperm DNA fragmentation during in vitro incubation.
P2860
Q33736865-4C17C213-9921-4693-9517-8D07E1BF2328Q34321877-AB188473-711A-4D26-942F-5845FD7FFCCAQ34583316-DE51E50F-E704-45D2-964B-038D76B6BC2EQ35161037-355BD9E0-17FE-4909-AC84-F09D67597FE9Q35547299-651E00E6-998F-46F2-BBD6-160400879CBDQ35609185-8794BBA8-BE51-47CD-BCAF-BF9E623B944CQ36580603-A314A079-DF9C-4D10-8E8F-3719228820EDQ36597244-2D5E79BC-28C0-4B5E-ABAF-1D3DBA682A77Q37053183-B39624E8-F8E6-4ADB-9C17-552BDB8D4E57Q37336090-22906A88-72B6-453E-A60F-9A27ABE2630DQ37346109-AB4DD7D1-B64F-400D-A725-059F422C825AQ37601287-68AE0AA6-A11D-4BC7-88FF-DAE5FE025DC0Q37602117-9CCFB761-451C-4DDF-B4E0-76F2C1ED6B69Q37828533-EDEEAAB5-9EF5-4CE4-9A33-B4B537456886Q37960522-42DD1129-E2FE-4C04-9135-CB55EEAE36F1Q38868174-27794DED-216B-46B0-A743-CA44B0D2B951Q40266830-14D06FCD-C049-4E4A-8FE3-0FE91BBE0BDAQ42717625-9EDDC3B4-917B-4DC8-AD8E-57866DC3DA7CQ45167319-A097501F-7F95-47B3-81F5-B4D0C14BB0B3Q46104100-82EE081A-DE71-4D16-A04E-FE72601255A9Q47938743-1E815891-A690-41F7-A933-4E944F73FF4BQ53097362-C65AA428-60DD-4164-A7A8-113BD098C690
P2860
Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Endocrine pharmacological char ...... stic and antagonistic activity
@ast
Endocrine pharmacological char ...... stic and antagonistic activity
@en
Endocrine pharmacological char ...... stic and antagonistic activity
@nl
type
label
Endocrine pharmacological char ...... stic and antagonistic activity
@ast
Endocrine pharmacological char ...... stic and antagonistic activity
@en
Endocrine pharmacological char ...... stic and antagonistic activity
@nl
prefLabel
Endocrine pharmacological char ...... stic and antagonistic activity
@ast
Endocrine pharmacological char ...... stic and antagonistic activity
@en
Endocrine pharmacological char ...... stic and antagonistic activity
@nl
P2093
P1433
P1476
Endocrine pharmacological char ...... stic and antagonistic activity
@en
P2093
P304
P356
10.1016/S0039-128X(00)00178-1
P407
P577
2000-01-01T00:00:00Z